Exploratory Cooperation on Fc-Engager Platform

LoopLab Bio is developing a proprietary Fc-Engager platform, a novel class of biologics designed to promote antigen-specific immune tolerance. By selectively engaging inhibitory Fc receptors together with disease-relevant antigens, Fc-Engagers aim to retrain the immune system rather than suppress it.

We warmly invite joint R&D collaborations with academic, biotech, and pharma partners to explore:

• Autoimmune & allergy: Celiac disease (gliadin), bullous pemphigoid (BP180), house dust mite allergy (Derp1/2)

• Rare diseases / ADA prevention: Pompe (ERT adjunct), Fabry (ERT adjunct), Pegloticase (gout, ADA prevention)

• Transplant tolerance: FcE adjunct concepts to address antibody rebound and re-dosing

These programs are at the exploratory, preclinical stage and illustrate the platform’s broad applicability. In addition, we are considering future applications in gene therapy, where tolerance induction could help reduce immune barriers to durable treatment.

Our interest is in co-developing translational models, sharing know-how, and applying Fc-Engager technology in indication-specific settings. We believe cooperation will help generate mutual value and advance the field of durable immune tolerance therapies.